MedPath

Chengdu Origen Biotechnology Co., Ltd.

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
4 (100.0%)

A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants with Neovascular Age-related Macular Degeneration

Phase 1
Not yet recruiting
Conditions
Age-Related Macular Degeneration
Interventions
First Posted Date
2025-02-13
Last Posted Date
2025-02-13
Lead Sponsor
Chengdu Origen Biotechnology Co., Ltd.
Target Recruit Count
9
Registration Number
NCT06825858

Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Phase 1
Recruiting
Conditions
Age-related Macular Degeneration
Interventions
First Posted Date
2024-06-13
Last Posted Date
2024-11-28
Lead Sponsor
Chengdu Origen Biotechnology Co., Ltd.
Target Recruit Count
44
Registration Number
NCT06458595
Locations
🇨🇳

Tianjin Medical University General Hospital, Tianjin, China

Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Phase 1
Recruiting
Conditions
Age-Related Macular Degeneration
Interventions
First Posted Date
2023-01-05
Last Posted Date
2024-11-27
Lead Sponsor
Chengdu Origen Biotechnology Co., Ltd.
Target Recruit Count
42
Registration Number
NCT05672121
Locations
🇨🇳

Beijing Tongren Hospital, Capital Medical University, Beijing, China

Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

Phase 1
Recruiting
Conditions
Age-Related Macular Degeneration
Interventions
First Posted Date
2022-12-20
Last Posted Date
2024-02-26
Lead Sponsor
Chengdu Origen Biotechnology Co., Ltd.
Target Recruit Count
25
Registration Number
NCT05657301
Locations
🇺🇸

Kanghong Investigative Site, Dallas, Texas, United States

News

First Patient Dosed in Phase 1 Trial of KH658 Gene Therapy for Wet AMD

Chengdu Origen and Vanotech have dosed the first patient in their VAN-2401 Phase 1 trial evaluating KH658, a gene therapy administered via a single suprachoroidal injection for wet AMD.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.